Inflammation and the mucosal microcirculation in inflammatory bowel disease: The ebb and flow

Current Opinion in Gastroenterology

Volumn 23, Issue 4, 2007, Pages 384-389

  Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Crohn's disease; Endothelium; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID DERIVATIVE; ANTIBIOTIC AGENT; AZATHIOPRINE; BIOLOGICAL MARKER; CORTICOSTEROID; CYTOKINE; EPIDERMAL GROWTH FACTOR; INTERFERON ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23; MERCAPTOPURINE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY CD3; PROBIOTIC AGENT; TACROLIMUS; THALIDOMIDE; TREFOIL PEPTIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY;

CLOSTRIDIUM; CYTOKINE PRODUCTION; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG TARGETING; ENTERITIS; ESCHERICHIA COLI; EVALUATION; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; IMMUNOMODULATION; IMMUNOPHENOTYPING; NONHUMAN; PSEUDOMONAS FLUORESCENS; REVIEW; SACCHAROMYCES;

BLOOD COAGULATION FACTOR INHIBITORS; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; REGIONAL BLOOD FLOW; T-LYMPHOCYTES;

EID: 34249944864     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32810c8de3     Document Type: Review

References (61)

1. Girard JP, Springer TA. High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today 1995; 16:449-457.
2. Granger DN, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994; 55:662-675.
3. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91:3527-3561.
4. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99:683-690.
5. Binion DG, West GA, Ina K, et al. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 1997; 112:1895-1907.
6. Gerlach E, Nees S, Becker BF. The vascular endothelium: a survey of some newly evolving biochemical and physiological features. Basic Res Cardiol 1985; 80:459-474.
7. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115:182-205.
8. Fiocchi C. Inflammatory bowel disease: dogmas and heresies. Dig Liver Dis 2002; 34:306-311.
9. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653-660.
10. Koutroubakis IE, Tsiolakidou G, Karmiris K, Kouroumalis EA. Role of angiogenesis in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:515-523. A comprehensive review on the importance of angiogenesis in IBD.
11. Szekanecz Z, Koch AE. Vascular endothelium and immune responses: implications for inflammation and angiogenesis. Rheum Dis Clin North Am 2004; 30:97-114.
12. Risau W. Mechanisms of angiogenesis. Nature 1997; 386:671-674.
13. Qu Z, Liebler JM, Powers MR, et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 1995; 147:564-573.
14. Scapini P, Nesi L, Morini M, et al. Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. J Immunol 2002; 168:5798-5804.
15. Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rheumatol 2005; 17:293-298.
16. Collin-Osdoby P, Rothe L, Bekker S, et al. Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J Bone Miner Res 2002; 17:1859-1871.
17. Crivellato E, Ribatti D. Involvement of mast cells in angiogenesis and chronic inflammation. Curr Drug Targets Inflamm Allergy 2005; 4:9-11.
18. Okada F. Inflammation and free radicals in tumor development and progression. Redox Rep 2002; 7:357-368.
19. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. NatMed 2000; 6:389-395.
20. Majno G. Chronic inflammation: links with angiogenesis and wound healing. Am J Pathol 1998; 153:1035-1039.
21. Frantz S, Vincent KA, Feron O, Kelly RA. Innate immunity and angiogenesis. Circ Res 2005; 96:15-26.
22. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130: 2060-2073. The first report demonstrating immune-driven angiogenesis in human IBD.
23. Bardin N, Reumaux D, Geboes K, et al. Increased expression of CD146, a new marker of the endothelial junction in active inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:16-21. An important study that further highlights the activation state of the microvasculature in IBD.
24. Saito S, Tsuno NH, Sunami E, et al. Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease. J Gastroenterol 2003; 38: 229-237.
25. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001; 96:822-828.
26. Shirasaka T, Iizuka M, Yukawa M, et al. Altered expression of epimorphin in ulcerative colitis. J Gastroenterol Hepatol 2003; 18:570-577.
27. Bousvaros A, Zurakowski D, Fishman SJ, et al. Serum basic fibroblast growth factor in pediatric Crohn's disease: implications for wound healing. Dig Dis Sci 1997; 42:378-386.
28. Matsuno M, Shiota G, Umeki K, et al. Clinical evaluation of hepatocyte growth factor in patients with gastrointestinal and pancreatic diseases with special reference to inflammatory bowel disease. Res Commun Mol Pathol Pharmacol 1997; 97:25-37.
29. Koutroubakis IE, Xidakis C, Karmiris K, et al. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur J Clin Invest 2006; 36:127-132. A report describing novel accessory molecules of inflammatory angiogenesis in IBD.
30. Danese S, Scaldaferri F, Graziani C, et al. Critical role of the CD40-CD40 ligand pathway in governing mucosal inflammation-driven angiogenesis in inflammatory bowel disease. Gut (in press).
31. Danese S, Sans M, Spencer D, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2006; 14 December [Epub ahead of print]. This paper describes the importance of angiogenesis blockade as a novel therapeutic approach for experimental IBD.
32. Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol 2006; 169:2014-2030. This paper describes the importance of angiogenesis blockade as a novel therapeutic approach for experimental IBD.
33. Goebel S, Huang M, Davis WC, et al. VEGF-A stimulation of leukocyte adhesion to colonic microvascular endothelium: implications for inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 2006; 290:G648-G654. A well performed study suggesting that VEGF, in addition to being an angiogenic mediator, may contribute to IBD pathogenesis by acting as a proinflammatory cytokine.
34. Danese S, de la Motte C, Sturm A, et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003; 124:1249-1264.
35. Power CA, Clemetson JM, Clemetson KJ, Wells TN. Chemokine and chemokine receptor mRNA expression in human platelets. Cytokine 1995; 7:479-482.
36. Devergne O, Marfaing-Koka A, Schall TJ, et al. Production of the RANTES chemokine in delayed-type hypersensitivity reactions: involvement of macrophages and endothelial cells. J Exp Med 1994; 179:1689-1694.
37. Russell J, Cooper D, Tailor A, et al. Low venular shear rates promote leukocyte-dependent recruitment of adherent platelets. Am J Physiol Gastrointest Liver Physiol 2003; 284:G123-G129.
38. Vowinkel T, Anthoni C, Wood KC, et al. CD40-CD40 Ligand mediates the recruitment of leukocytes and platelets in the inflamed murine colon. Gastroenterology (in press).
39. Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 2005; 3:617-628.
40. Danese S, Sans M, Scaldaferri F, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel antiinflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006; 176:2617-2624. This paper provides evidence on the role of TNF-α blockade in deactivation of microvascular inflammation in Crohn's disease.
41. Hulten L, Lindhagen J, Lundgren O, et al. Regional intestinal blood flow in ulcerative colitis and Crohn's disease. Gastroenterology 1977; 72:388-396.
42. Angerson WJ, Allison MC, Baxter JN, Russell RI. Neoterminal ileal blood flow after ileocolonic resection for Crohn's disease. Gut 1993; 34:1531-1534.
43. Guslandi M, Polli D, Sorghi M, Tittobello A. Rectal blood flow in ulcerative colitis. Am J Gastroenterol 1995; 90:579-580.
44. Bacaner MB. Quantitative measurement of regional colon blood flow in the normal and pathological human bowel. Gastroenterology 1966; 51:764-777.
45. Johansson H, Krause U, Olding L. Microangiographic studies in Crohn's disease and ulcerative colitis. Acta Chir Scand 1972; 138:409-414.
46. Appleyard CB, Alvarez A, Percy WH. Temporal changes in colonic vascular architecture and inflammatory mediator levels in animal models of colitis. Dig Dis Sci 2002; 47:2007-2014.
47. Kruschewski M, Foitzik T, Perez-Canto A, et al. Changes of colonic mucosal microcirculation and histology in two colitis models: an experimental study using intravital microscopy and a new histological scoring system. Dig Dis Sci 2001; 46:2336-2343.
48. McLaren WJ, Anikijenko P, Thomas SG, et al. In vivo detection of morphological and microvascular changes of the colon in association with colitis using fiberoptic confocal imaging (FOCI). Dig Dis Sci 2002; 47:2424-2433.
49. Foitzik T, Kruschewski M, Kroesen A, Buhr HJ. Does microcirculation play a role in the pathogenesis of inflammatory bowel diseases? Answers from intravital microscopic studies in animal models. Int J Colorectal Dis 1999; 14:29-34.
50. Appleyard CB, Williams JL, Hathaway CA, Percy WH. Temporal patterns of colonic blood flow and tissue damage in an animal model of colitis. Dig Dis Sci 1999; 44:431-438.
51. Carr N. Microvascular disease in the human large bowel. Gut 1996; 39:889-890.
52. Ravnic DJ, Konerding MA, Tsuda A, et al. Structural adaptations in the murine colon microcirculation associated with hapten-induced inflammation. Gut 2006; 17 November [Epub ahead of print]. An elegant investigation of the microvascular changes that occur in TNBS-induced experimental colitis.
53. Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: loss of nitric oxide-mediated vasodilation. Gastroenterology 2003; 125:58-69.
54. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by antialpha 4 integrin monoclonal antibody. J Clin Invest 1993; 92:372-380.
55. Muehlhoefer A, Saubermann LJ, Gu X, et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 2000; 164:3368-3376.
56. Macias WL, Yan SB, Williams MD, et al. New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated). Crit Care 2005; 9 (Suppl 4):S38-S45.
57. Aird WC. Natural anticoagulant inhibitors: activated protein C. Best Pract Res Clin Haematol 2004; 17:161-182.
58. O'Brien JM Jr, Abraham E. Human models of endotoxemia and recombinant human activated protein C. Crit Care Med 2004; 32 (5 Suppl):S202-S208.
59. Okajima K. Regulation of inflammatory responses by activated protein C: the molecular mechanism(s) and therapeutic implications. Clin Chem Lab Med 2004; 42:132-141.
60. Faioni EM, Ferrero S, Fontana G, et al. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit Care Med 2004; 32 (5 Suppl):S266-S270.
61. Scaldaferri F, Sans M, Graziani C, et al. Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease. J Clin Invest (in press).